Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma

Soochow University

Status and phase: Not yet enrolling; Phase 2

Conditions: Lymphoma, Non-Hodgkin

Treatments: Biological: Cytokine-induced killer cells (CIK)

Study type: Interventional

Funder types: Other

Identifiers

NCT02497898

RNHL001

Details and patient eligibility

About

The purpose of this study is to study the safety and efficacy of chemotherapy usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.

Full description

Autologous cytokine-induced killer (CIK) cells transfusion(>2*10^9 cells count) within 2 weeks after regular chemotherapy every 3 months.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosed as non-Hodgkin lymphoma with negative effect of regular chemotherapy, and need further therapy

Exclusion criteria

• patients refuse the therapy or have no tolerance for the therapy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

1,000 participants in 2 patient groups

regular chemotherapy

No Intervention group

Description:

Patients after chemotherapy are just followed up.

CIK regimen

Experimental group

Description:

Patients after chemotherapy will receive at least 3 cycles of Cytokine-induced killer cells (CIK) treatment every 3 months.

Treatment:

Biological: Cytokine-induced killer cells (CIK)